1. 首页
  2. 产品目录
  3. 标准品
  4. 药品杂质对照品
  5. 阿奇霉素杂质

阿奇霉素杂质10对照品（盐酸盐）

(2R,3S,4R,5R,8R,10R,11R,12S,13S,14R)-2-ethyl-3,4,10,11,13- pentahydroxy-3,5,6,8,10,12,14-heptamethyl-1-oxa-6- azacyclopentadecan-15-one （订货以CAS编码或英文名称为准）

创赛科技提供的所有产品仅用于科研等非医疗用途，非药品不可食用，不可用于人体或动物的临床诊断和治疗,我们不为个人提供产品及服务。如您需要产品COA等资料，可至下方“质量控制”中下载
编号：PC70146
分子式：C22H44CLNO7
CAS号：118456-11-4
分子量：470.04
储存条件：-20°C
申请试用
货号 品牌 规格 纯度/含量 标准价 优惠价 库存货期 数量 购买
PC70146-10mg Medlife 10mg
≥98%
 待询 登录后可见
PC70146-25mg Medlife 25mg
≥98%
 待询 登录后可见
PC70146-50mg Medlife 50mg
≥98%
 待询 登录后可见
PC70146-100mg Medlife 100mg
≥98%
 待询 登录后可见
中文名称： 阿奇霉素杂质10(盐酸盐)
中文别名： 阿奇霉素杂质10(盐酸盐)
英文名称： (2R,3S,4R,5R,8R,10R,11R,12S,13S,14R)-2-ethyl-3,4,10,11,13- pentahydroxy-3,5,6,8,10,12,14-heptamethyl-1-oxa-6- azacyclopentadecan-15-one
CAS号： 118456-11-4
分子式： C22H44CLNO7
分子量： 470.04
详细描述 仅用于研发试验中鉴别、检查。118456-11-4|阿奇霉素杂质10对照品（盐酸盐）,≥98%，制备中，详情请联系Medlife客服进行咨询。(2R,3S,4R,5R,8R,10R,11R,12S,13S,14R)-2-ethyl-3,4,10,11,13- pentahydroxy-3,5,6,8,10,12,14-heptamethyl-1-oxa-6- azacyclopentadecan-15-one可放大生产，批量保障。
搜索质检报告(COA)
相关产品
(2R,3S,4R,5R,8R,10R,11R,12S,13S,14R)-2-ethyl-3,4,10,11,13- pentahydroxy-3,5,6,8,10,12,14-heptamethyl-1-oxa-6- azacyclopentadecan-15-one
N-((2R,3R,4S,6R)-2-(((2R,3S,4R,5R,8R,10R,11R,12S,13S,14R)-2- ethyl-3,4,10-trihydroxy-13-(((2R,4R,5S,6S)-5-hydroxy-4-methoxy-4,6-dimethyltetrahydro-2H-pyran-2-yl)oxy)-3,5,6,8,10,12,14-heptamethyl-15-oxo-1-oxa-6-azacyclopentadecan-11-yl)oxy)-3-hydroxy-6-methyl tetrahydro-2H-pyran-4-yl)-N,4-dimethylbenzenesulfonamide
(3R,4S,5S,6R,7R,9R,11S,12R,13S,14R,E)-6-(((2R,3R,4S,6R)- 4-(dimethylamino)-3-hydroxy-6-methyltetrahydro-2H-pyran-2- yl)oxy)-14-ethyl-7,12,13-trihydroxy-4-(((2R,4R,5S,6S)-5- hydroxy-4-methoxy-4,6-dimethyltetrahydro-2H-pyran-2-yl) oxy)-10-(hydroxyimino)-3,5,7,9,11,13-hexamethyl oxacyclotetradecan-2-one
N-((2R,3R,4S,6R)-2-(((2R,3S,4R,5R,8R,10R,11R,12S,13S,14R)-2- ethyl-3,4,10-trihydroxy-13-(((2R,4R,5S,6S)-5-hydroxy-4-methoxy-4,6-dimethyltetrahydro-2H-pyran-2-yl)oxy)-3,5,6,8,10,12,14-heptamethyl-15-oxo-1-oxa-6-azacyclopentadecan-11-yl)oxy)-3-hydroxy-6-methyl tetrahydro-2H-pyran-4-yl)-N-methylformamide
N-(4-(N-((2R,3R,4S,6R)-2-(((2R,3S,4R,5R,8R,10R,11R,12S,13S,14R)-2-ethyl-3,4,10-trihydroxy-13-(((2R,4R,5S,6S)-5-hydroxy-4-methoxy-4,6-dimethyltetrahydro-2H-pyran-2-yl)oxy)-3,5,6,8,10,12,14-heptamethyl-15-oxo-1-oxa-6-azacyclopentadecan-11-yl)oxy)-3-hydroxy-6-methyltetrahydro-2H-pyran-4-yl)-N-methylsulfamoyl)phenyl)acetamide
(2R,3S,4R,5R,8R,10R,11R,12S,13S,14R)-11-(((2R,3R,4S,6R)- 4-(dimethylamino)-3-hydroxy-6-methyltetrahydro-2H-pyran-2-yl) oxy)-2-ethyl-3,4,10,13-tetrahydroxy-3,5,6,8,10,12,14-heptamethyl- 1-oxa-6-azacyclopentadecan-15-one
(2R,3S,4R,5R,8R,10R,11R,12S,13S,14R)-2-ethyl-3,4,10- trihydroxy-13-(((2R,4R,5S,6S)-5-hydroxy-4-methoxy-4,6- dimethyltetrahydro-2H-pyran-2-yl)oxy)-11-(((2R,3R,4S,6R)- 3-hydroxy-6-methyl-4-(methylamino)tetrahydro-2H-pyran-2- yl)oxy)-3,5,6,8,10,12,14-heptamethyl-1-oxa-6-azacyclopentadecan- 15-one
(2R,3R,4S,6R)-2-(((2R,3S,4R,5R,8R,10R,11R,12S,13S,14R)- 2-ethyl-3,4,10-trihydroxy-13-(((2R,4R,5S,6S)-5-hydroxy-4- methoxy-4,6-dimethyltetrahydro-2H-pyran-2-yl)oxy)-3,5,6, 8,10,12,14-heptamethyl-15-oxo-1-oxa-6-azacyclopentadecan- 11-yl)oxy)-3-hydroxy-N,N,6-trimethyltetrahydro-2H-pyran-4- amine oxide
(2R,3S,4R,5R,8R,10R,11R,12S,13S,14R)-2-ethyl-3,4,10- trihydroxy-13-(((2R,4R,5S,6S)-5-hydroxy-4-methoxy-4,6- dimethyltetrahydro-2H-pyran-2-yl)oxy)-11-(((2R,3R,4S,6R)- 3-hydroxy-6-methyl-4-(methylamino)tetrahydro-2H-pyran-2- yl)oxy)-3,5,6,8,10,12,14-heptamethyl-1-oxa-6-azacyclopentadecan- 15-one
(2R,3S,4R,5R,8R,10R,11R,12S,13S,14R)-2-ethyl-3,4,10,11,13- pentahydroxy-3,5,6,8,10,12,14-heptamethyl-1-oxa-6- azacyclopentadecan-15-one